Table 2.
Adverse events reported in the included randomised controlled trials.
| Adverse events | Studies reporting (n) | ACEI/ARB group (n/n) | Control group (n/n) | OR (95% CI) | P value |
|---|---|---|---|---|---|
| Total patients with adverse events | 8 | 92/2030 | 50/2608 | 2.44 (1.72–3.46) | <0.001* |
| Specific adverse events | |||||
| Hyperkalemia | 6 | 52/1855 | 25/2433 | 2.26 (1.42–3.61) | 0.001* |
| Hypotension | 5 | 23/141 | 9/159 | 2.31 (0.80–6.67) | 0.12 |
| Cough | 4 | 2/68 | 2/67 | 0.82 (0.00–1537.21) | 0.96 |
| Oedema | 4 | 4/97 | 14/114 | 0.46 (0.16–1.35) | 0.16 |
OR: odds ratio; CI: confidence interval.
*
P<0.05 was considered significant.